Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.44 |
| ▸ | ABL2 | P42684 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16460322 | 0.89 | TGFBR1 (0.60) | TGFBR1MAPK14THRB | |
| SCHEMBL12270041 | 0.84 | TGFBR1 (0.67) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL3244123 | 0.82 | TGFBR1 (0.63) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL376179 | 0.81 | TGFBR1 (0.67) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL5875521 | 0.81 | TGFBR1 (0.60) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL18642502 | 0.79 | GRM4 (0.65) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL4030836 | 0.79 | TGFBR1 (0.61) | TGFBR1MAPK14THRBTGFBR2 | |
| SCHEMBL7918743 | 0.79 | MAPT (0.56) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| Fluoromethane SCHEMBL27755992 | 0.79 | TGFBR1 (0.64) | TGFBR1MAPK14THRBTGFBR2ABL2 | |
| SCHEMBL28018855 | 0.79 | GRM4 (0.46) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | claimed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981944-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| US-20160264553-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-15 | — | — | US | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264553-A1 | GDF-8 Inhibitors | CXCL8, MSTN, LGALS8 | TGFBR1 249/4885MAPK14 2158/4885THRB 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.